

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

INSIDE INFORMATION ANNOUNCEMENT

UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC

This announcement is made by Alphamab Oncology (the “**Company**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the inside information announcement of the Company dated November 14, 2023. The Company wishes to provide further updates in relation to KN046-303, a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial designed to evaluate the efficacy and safety of KN046 in combination with nab-paclitaxel/gemcitabine versus placebo in combination with nab-paclitaxel/gemcitabine, for the treatment of patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) without systemic treatment.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the preset number of death events for KN046-303 was reached. Analysis indicates that the overall survival (OS) result did not reach the preset statistical endpoint.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market, KN046 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board

Alphamab Oncology

Dr. XU Ting

Chairman and Executive Director

Hong Kong, May 28, 2024

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.